Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of …
Background Molecularly targeted agents have been reported to have anti-tumour activity for
patients whose tumours harbour the matching molecular alteration. These results have led …
patients whose tumours harbour the matching molecular alteration. These results have led …
SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma
SJ Furney, M Pedersen, D Gentien, AG Dumont… - Cancer discovery, 2013 - AACR
Uveal melanoma, the most common eye malignancy, causes severe visual morbidity and is
fatal in approximately 50% of patients. Primary uveal melanoma can be cured by surgery or …
fatal in approximately 50% of patients. Primary uveal melanoma can be cured by surgery or …
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
…, M Lacroix-Triki, L Lacroix, P Cohen, D Gentien… - The lancet …, 2014 - thelancet.com
Background Breast cancer is characterised by genomic alterations. We did a multicentre
molecular screening study to identify abnormalities in individual patients with the aim of …
molecular screening study to identify abnormalities in individual patients with the aim of …
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international …
…, F Jardin, F Offner, P Sujobert, D Gentien… - The lancet …, 2018 - thelancet.com
Background Patients with follicular lymphoma have heterogeneous outcomes. Predictor
models to distinguish, at diagnosis, between patients at high and low risk of progression are …
models to distinguish, at diagnosis, between patients at high and low risk of progression are …
[HTML][HTML] Molecular profiling of patient-derived breast cancer xenografts
…, N Auger, F Assayag, L De Plater, D Gentien… - Breast cancer …, 2012 - Springer
Introduction Identification of new therapeutic agents for breast cancer (BC) requires preclinical
models that reproduce the molecular characteristics of their respective clinical tumors. In …
models that reproduce the molecular characteristics of their respective clinical tumors. In …
Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges
…, M Hasan, B Albaud, D Gentien… - Proceedings of the …, 2018 - National Acad Sciences
The contribution of host genetic and nongenetic factors to immunological differences in
humans remains largely undefined. Here, we generated bacterial-, fungal-, and viral-induced …
humans remains largely undefined. Here, we generated bacterial-, fungal-, and viral-induced …
Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer
…, B Marty-Prouvost, L De Koning, G Lang, D Gentien… - Cancer research, 2013 - AACR
Breast cancers are composed of molecularly distinct subtypes with different clinical outcomes
and responses to therapy. To discover potential therapeutic targets for the poor prognosis-…
and responses to therapy. To discover potential therapeutic targets for the poor prognosis-…
Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors
…, A Dahmani, MA Bessard, D Gentien… - Clinical cancer …, 2010 - AACR
Purpose: Uveal melanoma is the most common primary intraocular malignant tumor in adults
and is defined by a poor natural outcome, as 50% of patients die from metastases. The aim …
and is defined by a poor natural outcome, as 50% of patients die from metastases. The aim …
High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients
…, C Plancher, C Reyes, B Albaud, A Rapinat, D Gentien… - Cancer research, 2011 - AACR
A high percentage of uveal melanoma patients develop metastatic tumors predominantly in
the liver. We studied the molecular profiles derived from gene expression microarrays and …
the liver. We studied the molecular profiles derived from gene expression microarrays and …
[HTML][HTML] TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer
…, L De Koning, G Rigaill, A Dumont, D Gentien… - PloS one, 2013 - journals.plos.org
Triple-negative breast cancer (TNBC) represents a subgroup of breast cancers (BC) associated
with the most aggressive clinical behavior. No targeted therapy is currently available for …
with the most aggressive clinical behavior. No targeted therapy is currently available for …